Back to Stocks

CCRN

CROSS COUNTRY HEALTHCARE INC
7 filings tracked
healthcarehealthcare staffingMID ($2B-10B)

Company Intelligence Hub

Filing history, signal momentum, and bull/bear evolution

Chronological Filing Evolution (Click to filter / toggle)

Thesis (Bull Case Evolution)

Cross Country Healthcare is executing a strategic pivot from a cyclical staffing operator to a streamlined acquisition target.…

Bullish Outlook

Antithesis (Bear Case / Structural Risks)

Despite the narrative of a disciplined reset, the underlying fundamentals of Cross Country Healthcare show a business in significant decline. Revenue plummeted nearly 18% year-over-year, driven by a sharp contraction in both nurse and physician staffing volumes.…

Risk Factors

Read the full bull/bear analysis

You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every CCRN filing.

Start Free Trial

Synthesis (Verdict & Resolution)

The Q1 2026 filing presents a stark contrast between a deteriorating operational core and a highly attractive financial exit strategy. While the business is struggling with a 17.8% revenue decline and shrinking margins, the company's financial engineering—specifically the use of cash for share buybacks and the maintenance of a debt-free balance sheet—has created a floor for the stock. The operational headwinds are real, but they are currently being offset by the certainty of a pending merger. Ultimately, the investment thesis has shifted from a growth story to a merger arbitrage play. The critical path for investors is no longer the recovery of the healthcare staffing market, but rather the successful closing of the merger by October 2026. Until then, the company's ability to maintain its liquidity and avoid covenant breaches on its credit facility will be the primary metrics of concern.

Selected Quarter

Core Takeaway

The company is experiencing a severe operational downturn but is positioning itself for a high-value all-cash acquisition.

Investor Lens

The trade-off between the risk of the merger failing and the ability to capture a premium on a declining asset.

Watch Next

The October 6, 2026 merger deadline and stockholder approval vote.

View Full SEC Report

Signal Momentum Chart

Quarterly net bull/bear signal ratio. Click nodes to select a quarter.

BULLISH (+1.0)NEUTRAL (0.0)BEARISH (-1.0)+0.04Q2 '26 (10-Q)

Signal Timeline

Active Filters:Quarter: Q2 '26 (10-Q)
bearishMay 8

Net loss widened to $4.3 million from $0.5 million year-over-year.

earnings miss
90%
bullishMay 8

Entered definitive merger agreement to be acquired at $13.25 per share.

acquisition
95%
bullishMay 8

Repurchased 657,653 shares at an average price of $8.86.

buyback
70%
bearishMay 8

Nurse and Allied contribution margin fell from 7.1% to 6.3%.

margin compression
60%
bearishMay 8

Net loss widened to $4.3 million from $0.5 million year-over-year.

earnings miss
90%
bullishMay 8

Entered definitive merger agreement to be acquired at $13.25 per share.

acquisition
95%
bullishMay 8

Repurchased 657,653 shares at an average price of $8.86.

buyback
70%
bearishMay 8

Nurse and Allied contribution margin fell from 7.1% to 6.3%.

margin compression
60%
bearishMay 8

Net loss widened to $4.3 million from $0.5 million year-over-year.

earnings miss
90%
bullishMay 8

Entered definitive merger agreement to be acquired at $13.25 per share.

acquisition
95%
bullishMay 8

Repurchased 657,653 shares at an average price of $8.86.

buyback
70%
bearishMay 8

Nurse and Allied contribution margin fell from 7.1% to 6.3%.

margin compression
60%
bearishMay 8

Net loss widened to $4.3 million from $0.5 million year-over-year.

earnings miss
90%
bullishMay 8

Entered definitive merger agreement to be acquired at $13.25 per share.

acquisition
95%
bullishMay 8

Repurchased 657,653 shares at an average price of $8.86.

buyback
70%
bearishMay 8

Nurse and Allied contribution margin fell from 7.1% to 6.3%.

margin compression
60%
bearishMay 8

Net loss widened to $4.3 million from $0.5 million year-over-year.

earnings miss
90%
bullishMay 8

Entered definitive merger agreement to be acquired at $13.25 per share.

acquisition
95%
bullishMay 8

Repurchased 657,653 shares at an average price of $8.86.

buyback
70%
bearishMay 8

Nurse and Allied contribution margin fell from 7.1% to 6.3%.

margin compression
60%
bearishMay 8

Net loss widened to $4.3 million from $0.5 million year-over-year.

earnings miss
90%
bullishMay 8

Entered definitive merger agreement to be acquired at $13.25 per share.

acquisition
95%
bullishMay 8

Repurchased 657,653 shares at an average price of $8.86.

buyback
70%
bearishMay 8

Nurse and Allied contribution margin fell from 7.1% to 6.3%.

margin compression
60%
bearishMay 8

Net loss widened to $4.3 million from $0.5 million year-over-year.

earnings miss
90%
bullishMay 8

Entered definitive merger agreement to be acquired at $13.25 per share.

acquisition
95%
bullishMay 8

Repurchased 657,653 shares at an average price of $8.86.

buyback
70%
bearishMay 8

Nurse and Allied contribution margin fell from 7.1% to 6.3%.

margin compression
60%

Filing History

10-QMay 8, 2026
Expand Sequence

The Q1 2026 filing presents a stark contrast between a deteriorating operational core and a highly attractive financial exit strategy. While the business is struggling with a 17.8% revenue decline and shrinking margins, the company's financial engineering—specifically the use of cash for share buybacks and the maintenance of a debt-free balance sheet—has created a floor for the stock. The operational headwinds are real, but they are currently being offset by the certainty of a pending merger. Ultimately, the investment thesis has shifted from a growth story to a merger arbitrage play. The critical path for investors is no longer the recovery of the healthcare staffing market, but rather the successful closing of the merger by October 2026. Until then, the company's ability to maintain its liquidity and avoid covenant breaches on its credit facility will be the primary metrics of concern.

Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.